A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Tina CasconeBoris SepesiHeather Y LinNeda KalhorEdwin Roger Parra CuentesMei JiangMyrna C B GodoyJianjun ZhangFrank V FossellaAnne S TsaoVincent K LamCharles LuFrank E MottGeorge R SimonMara B AntonoffReza J MehranDavid C RiceCarmen BehrensAnnikka WeissferdtCesar MoranAra A VaporciyanJ Jack LeeStephen G SwisherDon L GibbonsIgnacio I WistubaWilliam N WilliamJohn Victor HeymachPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Although tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls. Additional studies of the combination in this setting are not recommended. Posttreatment levels of tumor-infiltrating T cells were associated with patient survival. Use of MPR facilitates the rapid evaluation of neoadjuvant therapies.See related commentary by Blakely and McCoach, p. 3499.